Zhengzhou Weixian Medical Technology Co., Ltd.

Primary objective: To observe the pharmacokinetic characteristics of the test preparation metformin empagliflozin tablets (specification: each tablet contains 850 mg of metformin hydrochloride and 12.5 mg of empagliflozin) and the reference preparation metformin empagliflozin tablets (trade name: Synjardy®; specification: each tablet contains 850 mg of metformin hydrochloride and 12.5 mg of empagliflozin; licensee: Boehringer Ingelheim International GmbH) after a single oral administration in the fasting/postprandial state in healthy Chinese subjects, and to preliminarily evaluate the bioequivalence of the two preparations in the fasting/postprandial state. Secondary objective: To observe the safety of the test preparation metformin empagliflozin tablets and the reference preparation metformin empagliflozin tablets (Synjardy ®) in healthy Chinese subjects.

"Primary objective: To observe the pharmacokinetic characteristics of the test preparation safinamide mesylate tablets (specification: 100 mg based on C17H19FN2O2; manufacturer: Shenzhen Xinlitai Pharmaceutical Co., Ltd.) and the reference preparation safinamide mesylate tablets (trade name: Xadago®; specification: 100 mg based on C17H19FN2O2; licensee and manufacturer: Zambon S.p.A.) in Chinese healthy subjects after a single oral administration in the fasting/postprandial state, and to evaluate the bioequivalence of the two preparations in the fasting/postprandial state. Secondary objective: To observe the safety of the test preparation safinamide mesylate tablets and the reference preparation safinamide mesylate tablets (Xadago®) in Chinese healthy subjects."